A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Neoadjuvant

Interventions

DRUG: Carboplatin
DRUG: Mirvetuximab Soravtansine
DRUG: Bevacizumab

Sponsor

AbbVie

Collaborators

[object Object]